Linkedin
Sign in
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Type here...
Search
Home
About
Editor’s Corner
Contribute
Contact Us
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
Solutions & Pricing
Partner
Instagram
Linkedin
Twitter
Subscribe
Subscribe
Saturday, March 28, 2026
24.7
C
Bengaluru
Home
About
Editor’s Corner
Contribute
Contact Us
My account
Get into your account.
Login
Register
type here...
Search
Facebook
Linkedin
Twitter
Youtube
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
How a Delhi Dementia Daycare Is Reimagining Care for India’s Forgotten Millions
0
By MedicinMan Editorial Desk When Memory Fades, Humanity Must Not In...
Aflibercept: When Originators Stop Fighting and Start Licensing
0
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
Customer Engagement and Experience are the New Differentiators
0
At the IDMA Marketing and Sales Conference in Mumbai...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
0
A market analysis and clinical commentary on the growing...
Is America’s “Miracle Shot” Worth the Hype and Risk? A Verified Look at the Claims
0
Introduction:An email circulating from Visibility Nexus references America’s “hottest...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Marketing
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Policies/Sales
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Strategy
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Subscribe
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
Debasish Banerjee’s Journey from Medical Rep to Chief Compliance Officer
0
For a person wanting to be a doctor, my...
Digital Marketing Kick Starter for Pharma Marketers
0
An interview with Salil Kallianpur - Executive VP at GSK Primary Care on the state of digital in pharma marketing and pointers for digital marketing success.
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
0
In an earlier article in The Wire Science, I...
Indian Pharma in September 2025: Momentum, Disruption & Caution
0
Indian Pharma in September 2025: Momentum, Disruption & Caution By...
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Marketing
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Policies/Sales
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Strategy
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Subscribe
author-and-co-author